Are you Dr. Dennis?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 90 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4940 Eastern Ave
Johns Hopkins Bayview Medical Center
Baltimore, MD 21224Phone+1 410-550-9250Fax+1 410-550-5445- Is this information wrong?
Summary
- Dr. Phillip Dennis, MD is an oncologist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1995 - 1998- Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
New York University School of MedicineClass of 1992
Certifications & Licensure
MD State Medical License 1995 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Elected Member The American Society for Clinical Investigation, 2007
Clinical Trials
- Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Start of enrollment: 2012 May 01
- Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2013 May 01
Publications & Presentations
PubMed
- 19 citationsDurvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).Mark A. Socinski, Mustafa Ozguroglu, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Jhanelle E. Gray, Keunchil Park, M. Vincent, Helen Mann, Mi...> ;Clinical Lung Cancer. 2021 Jun 12
- 2 citationsPatient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancerMarina Chiara Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Ozguroglu, Davey B. Daniel, David Vicente, Shuji Murakami, ...> ;Future Oncology. 2021 Feb 15
- 23 citationsImpact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, Mustafa Ozguroglu, Davey B. Daniel, A. Villegas, David Vicente, Rina Hui, Shuji...> ;Lung Cancer. 2021 Jan 1
- Join now to see all
Press Mentions
Post-Trial NSCLC Immunotherapy: Do Positive Vibes Linger On?September 13th, 2019
